tyrosine-chlorambucil hybrid

Tyrosine-chlorambucil hybrids represent a novel class of amino acid-linked nitrogen mustard conjugates designed for site-specific drug targeting in hormone-dependent gynecological and breast cancers. Developed by researchers at the Université du Québec à Trois-Rivières, these molecules utilize tyrosine as a scaffold to mimic the structure of 17β-estradiol, specifically leveraging the tyrosine phenol group to target estrogen receptor alpha (ERα). By conjugating the cytotoxic nitrogen mustard chlorambucil to this tyrosine moiety, the hybrids are intended to selectively deliver DNA-alkylating activity to ERα-overexpressing tumor cells, thereby improving the therapeutic index and reducing systemic toxicity compared to chlorambucil alone. Preclinical in vitro studies have demonstrated that these hybrids possess significantly higher biological activity (up to 10-fold) than the parent drug across various estrogen-dependent and independent human cancer cell lines, including MCF-7, Ishikawa, and OVCAR-3.

Other names

amino acid-linked nitrogen mustard hybrids